These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1030 related items for PubMed ID: 17632171

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB, Zeng FH, Sun ZQ.
    Chin Med J (Engl); 2006 Nov 05; 119(21):1821-8. PubMed ID: 17097038
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C, Ku JH, Park JY, Lee E, Lee SE, Lee C.
    J Urol; 2004 Jan 05; 171(1):149-52. PubMed ID: 14665864
    [Abstract] [Full Text] [Related]

  • 5. [A clinical study of recurrence and progression of grade 3 superficial bladder tumor].
    Ikegami S, Tsuji A, Suzuki S, Sumitomo M, Kimura F, Asano T, Nakajima F, Hayakawa M.
    Hinyokika Kiyo; 1999 May 05; 45(5):325-9. PubMed ID: 10410314
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T, Nesi G, Boddi V, Mazzoli S, Dal Canto M, Bartoletti R.
    Oncol Rep; 2006 Aug 05; 16(2):329-34. PubMed ID: 16820911
    [Abstract] [Full Text] [Related]

  • 9. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC, Lin AT, Chen KK, Chang LS.
    Int J Urol; 2006 Jun 05; 13(6):682-5. PubMed ID: 16834642
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.
    J Urol; 1995 Jul 05; 154(1):237-41. PubMed ID: 7776437
    [Abstract] [Full Text] [Related]

  • 12. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
    Guney S, Guney N, Canogullari Z, Ergenekon E.
    Urol Int; 2008 Jul 05; 80(2):124-8. PubMed ID: 18362479
    [Abstract] [Full Text] [Related]

  • 13. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May 05; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 14. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD, Sosa RE, Vaughan ED, Scherr DS.
    Urology; 2007 Feb 05; 69(2):251-4. PubMed ID: 17320658
    [Abstract] [Full Text] [Related]

  • 15. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M.
    Eur Urol; 2004 Jun 05; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [Abstract] [Full Text] [Related]

  • 16. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr 05; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 17. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE.
    Cancer; 2003 Oct 15; 98(8):1649-57. PubMed ID: 14534881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.